Ecuador vs Indonesia: Average cost of multi drug-resistant tuberculosis treatment
Ecuador
1,121 constant 2022 US$
in 2024
Indonesia
1,138 constant 2022 US$
in 2024
Ecuador rank
42nd
Indonesia rank
41st
Average cost of multi drug-resistant tuberculosis treatment over time
- Ecuador
- Indonesia
How they compare
Indonesia currently reports 1,138 constant 2022 US$ against 1,121 constant 2022 US$ in Ecuador, a difference of 17 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Indonesia ahead.
Ecuador ranks 42nd and Indonesia ranks 41st of 92 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ecuador | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 754 constant 2022 US$ | 1,463 constant 2022 US$ | 709.33 constant 2022 US$ | Indonesia |
| 2020s | 1,440 constant 2022 US$ | 1,466 constant 2022 US$ | 26.2 constant 2022 US$ | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Ecuador or Indonesia?
- Indonesia, at 1,138 constant 2022 US$ against 1,121 constant 2022 US$ in Ecuador as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Ecuador and Indonesia?
- 17 constant 2022 US$, with Indonesia ahead.
- How many years of comparable data are there for Ecuador and Indonesia?
- 8 years are reported by both, from 2017 to 2024.
- How do Ecuador and Indonesia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Ecuador ranks 42nd and Indonesia ranks 41st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.